

Table 3a. Systematic Reviews on PDE5i

Author Year; Country Score Research Design Total Sample Size	Methods Databases	Results
<p>Tienforti et al. 2024 Italy</p> <p>Reviewed published studies up to September 2023</p> <p>N=10</p> <p>Quality was assessed by Cochrane Collaboration Recommendations assessment tools.</p> <p>Type of studies randomized control trials (N=10)</p>	<p>Objective: To assess the efficacy of the different PDE5i for SCI-related ED with a network meta-analysis (NMA) approach</p> <p>Databases: PubMed, Scopus, Web of Science and Cochrane Library (up to September 2023)</p>	<ol style="list-style-type: none"> 1. The 10 RCTs provided information about 1,492 men with ED due to traumatic SCI. Intervention arms included sildenafil, tadalafil, and/or vardenafil. 2. In the pairwise meta-analysis, PDE5i's were four times more effective than placebo in improving erectile function (risk ratio: 4.13, 95% CI: 2.76, 6.19). 3. Tadalafil had the ranked highest effectiveness (SUCRA value) (81%) then vardenafil (68%), and sildenafil (49%).